ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

T-cell Depletion vs. Il-2 Receptor Blockade in Pancreas Transplantationt-Cell Depletion vs. Il-2 Receptor Blockade in Pancreas Transplantation

F. Aziz, S. Parajuli, D. Kaufman, J. Odorico, D. Mandelbrot

University of Wisconsin, Madison, WI

Meeting: 2022 American Transplant Congress

Abstract number: 1172

Keywords: Induction therapy

Topic: Clinical Science » Pancreas » 65 - Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Because of the higher immunological risk associated with pancreas compared to kidney transplantation, many have assumed that T depleting induction is required for pancreas recipients. However, limited data exists on relative outcomes with T depletion versus IL-2 receptor (IL2R) blockade in pancreas transplantation.

*Methods: We analyzed the records of all patients who underwent simultaneous pancreas- kidney (SPK) or pancreas transplant alone (PTA) at our institution between 01/01/2011 and 12/31/2019. We compared T-cell depletion to IL2R blockade for patient and pancreas allograft survival, rejection, and infectious complications.

*Results: Of 417 pancreas transplant recipients, 291 received induction with a T-depleting agent and 126 received induction with an IL2R blocker. The mean follow-up post-transplant was 5.3 ± 3 years. No difference was detected in pancreas allograft death censored (p=0.7) or uncensored (p=0.5) survival. CMV and bacterial infections were significantly more common in the patients who received T-cell depleting agents for induction (21% vs 11%, p=0.03; 34% vs 23%, p=0.04, respectively). On multivariate analysis, history of pancreas rejection (HR=3.80, p<0.0001; 95% Cl 2.28 to 6.33) and history of previously failed pancreas allograft (HR=2.10, p=0.02; 95% Cl 1.11 to 3.97) were associated with increased risk of pancreas allograft loss, but choice of induction was not (HR=0.78, p=0.37; 95% Cl 0.45 to 1.33). Further, on multivariate analysis, CMV infection (HR=1.78, p=0.01; 95% Cl 1.11 to 2.87) was associated with increased risk of pancreas allograft rejection, but choice of induction was not (HR=0.84, p=0.46; 95% Cl 0.54 to 1.32). Similarly, further analyses showed bacterial infection was associated with increased risk of patient death (HR=2.94, p=0.04; 95% Cl 1.03 to 8.32) but choice of induction was not (HR= 0.94 p=0.91; 95% Cl 0.32 to 2.71).

*Conclusions: In appropriately selected patients, patient and pancreas allograft survival were not different between the patients who received induction with T-depleting agents versus IL2R blockade. However, bacterial and CMV infection rates were higher in patients who received a T-cell depleting agent for induction. We suggest that IL-2 receptor blockade may be a reasonable choice of induction for pancreas transplant recipients at low immunological risk.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Aziz F, Parajuli S, Kaufman D, Odorico J, Mandelbrot D. T-cell Depletion vs. Il-2 Receptor Blockade in Pancreas Transplantationt-Cell Depletion vs. Il-2 Receptor Blockade in Pancreas Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/t-cell-depletion-vs-il-2-receptor-blockade-in-pancreas-transplantationt-cell-depletion-vs-il-2-receptor-blockade-in-pancreas-transplantation/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences